News

ISTA has declared positive results for Phase-II clinical study in subjects with dry eye disease (keratoconjuctivitis sicca). The company used its proprietary, low-dose formulation of bromfenac, the active

Progenics and Ono Pharmaceutical announced that they have started clinical testing of RELISTOR (methylnaltrexone bromide) subcutaneous injection in Japan. Its the first in class medicine approved in the

Active Biotech has announced that patient enrollment to the phase II clinical trial for TASQ, a novel compound for the treatment of prostate cancer, is completed. The company

Afinitor (everolimus) tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease. Based on results from this study and other early-stage research,

Alnylam and Cubist have reported preliminary data from their Phase II study of Aln-Rsv01, an RNAi therapeutic in development for the treatment of respiratory syncytial virus (RSV) infection.

Rx for Africa has announced the signing of letter of intent for a strategic alliance with Rusan Pharma of Mumbai, India. The alliance commences immediately, with Rusan providing

Sangamo has announced positive Phase-II clinical data from its ZFP Therapeutic program, to develop SB-509 as a treatment for diabetic neuropathy (DN). Data from SB-509-601 and SB-509-701A Phase

Micromet has announced that the German Multicenter ALL Study Group (GMALL) presented phase-II clinical data of the BiTE antibody blinatumomab (MT103) at the 14th Congress of the European

Lundbeck and Takeda jointly announced headline results from the first three clinical trials in the phase III development program with Lu AA21004, in major depressive disorder (MDD). Previously